Cartesian Therapeutics Stock Today
| RNAC Stock | 16.05 0.12 0.75% |
PerformanceVery Weak
| Odds Of DistressLow
|
Cartesian Therapeutics is trading at 16.05 as of the 22nd of March 2025, a 0.75% up since the beginning of the trading day. The stock's open price was 15.93. Cartesian Therapeutics has about a 20 % chance of experiencing some form of financial distress in the next two years of operation but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 22nd of December 2024 and ending today, the 22nd of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 22nd of June 2016 | Category Healthcare | Classification Health Care |
Cartesian Therapeutics is entity of United States. It is traded as Stock on NASDAQ exchange. The company has 25.91 M outstanding shares of which 2.02 M shares are at this time shorted by private and institutional investors with about 32.3 trading days to cover. More on Cartesian Therapeutics
Moving against Cartesian Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Cartesian Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| President CEO | Carsten Brunn | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsCartesian Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Cartesian Therapeutics' financial leverage. It provides some insight into what part of Cartesian Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Cartesian Therapeutics (RNAC) is traded on NASDAQ Exchange in USA. It is located in 7495 New Horizon Way, Frederick, MD, United States, 21703 and employs 66 people. Cartesian Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 412.7 M. Cartesian Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 25.91 M outstanding shares of which 2.02 M shares are at this time shorted by private and institutional investors with about 32.3 trading days to cover.
Cartesian Therapeutics currently holds about 106.44 M in cash with (23.67 M) of positive cash flow from operations.
Check Cartesian Therapeutics Probability Of Bankruptcy
Ownership AllocationCartesian Therapeutics holds a total of 25.91 Million outstanding shares. Cartesian Therapeutics retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Cartesian Ownership Details
Cartesian Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Northern Trust Corp | 2024-12-31 | 95 K | |
| Nuveen Asset Management, Llc | 2024-12-31 | 72.1 K | |
| Ikarian Capital, Llc | 2024-12-31 | 52.2 K | |
| Goldman Sachs Group Inc | 2024-12-31 | 27.5 K | |
| Charles Schwab Investment Management Inc | 2024-12-31 | 26.8 K | |
| Freestone Capital Holdings, Llc | 2024-12-31 | 25.9 K | |
| Morgan Stanley - Brokerage Accounts | 2024-12-31 | 24.3 K | |
| Delphi Financial Group Inc | 2024-12-31 | 22 K | |
| Alps Advisors Inc | 2024-12-31 | 20.6 K | |
| Fmr Inc | 2024-12-31 | 2.4 M | |
| Mpm Oncology Impact Management Lp | 2024-12-31 | 721.1 K |
Cartesian Therapeutics Historical Income Statement
Cartesian Stock Against Markets
Cartesian Therapeutics Corporate Management
| Emily English | SVP Manufacturing | Profile | |
| Peter MD | Chief Officer | Profile | |
| Milos MD | Chief Officer | Profile | |
| Blaine Davis | Chief Officer | Profile | |
| Matthew JD | General Secretary | Profile | |
| Metin MD | Chief Officer | Profile | |
| Yi Zhang | Senior Technology | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Cartesian Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade Cartesian Stock refer to our How to Trade Cartesian Stock guide.You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cartesian Therapeutics. If investors know Cartesian will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cartesian Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.537 | Earnings Share (4.49) | Revenue Per Share | Quarterly Revenue Growth (0.94) | Return On Assets |
The market value of Cartesian Therapeutics is measured differently than its book value, which is the value of Cartesian that is recorded on the company's balance sheet. Investors also form their own opinion of Cartesian Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Cartesian Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cartesian Therapeutics' market value can be influenced by many factors that don't directly affect Cartesian Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cartesian Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cartesian Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cartesian Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.